HC Wainwright Forecasts Reduced Earnings for TG Therapeutics

Key Points

• HC Wainwright cut its Q2 2026 EPS estimate for TG Therapeutics to $0.22 from $0.36, while keeping a Buy rating and $77 price target on the stock.
• TG Therapeutics’ most recent quarterly results missed EPS expectations, reporting $0.12 per share versus the $0.23 consensus, even as revenue came in above estimates at $204.92 million.
• Despite the near-term earnings downgrade, analysts still see longer-term growth potential, with a consensus rating of Moderate Buy and several firms projecting higher earnings in later years.

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - HC Wainwright dropped their Q2 2026 EPS estimates for shares of TG Therapeutics in a report released on Monday, July 13th. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will post earnings per share of $0.22 for the quarter, down from their previous forecast of $0.36. HC Wainwright has a "Buy" rating and a $77.00 price objective on the stock. The consensus estimate for TG Therapeutics' current full-year earnings is $1.51 per share. HC Wainwright also issued estimates for TG Therapeutics' Q3 2026 earnings at $0.28 EPS, FY2026 earnings at $0.99 EPS, FY2028 earnings at $3.81 EPS, FY2029 earnings at $4.70 EPS and FY2030 earnings at $5.84 EPS.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.11). The company had revenue of $204.92 million during the quarter, compared to analyst estimates of $200.33 million. TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The firm's revenue was up 69.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.03 earnings per share.

A number of other equities research analysts have also issued reports on TGTX. Weiss Ratings raised TG Therapeutics from a "hold (c)" rating to a "hold (c+)" rating in a research report on Friday, May 1st. Jefferies Financial Group restated a "buy" rating and set a $83.00 target price on shares of TG Therapeutics in a research note on Monday, June 22nd. Bank of America raised their target price on shares of TG Therapeutics from $17.00 to $20.00 and gave the company an "underperform" rating in a report on Tuesday, July 7th. Finally, Zacks Research upgraded shares of TG Therapeutics from a "strong sell" rating to a "hold" rating in a report on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $53.33.

TG Therapeutics Trading Down 0.2%

TGTX opened at $54.89 on Wednesday. The business has a fifty day moving average price of $46.98 and a 200 day moving average price of $36.68. The company has a debt-to-equity ratio of 1.28, a current ratio of 5.81 and a quick ratio of 5.12. TG Therapeutics has a 12 month low of $25.28 and a 12 month high of $59.30. The stock has a market capitalization of $8.40 billion, a price-to-earnings ratio of 19.19, a PEG ratio of 1.33 and a beta of 1.60.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Danske Bank A S acquired a new stake in TG Therapeutics during the 3rd quarter worth $25,000. EverSource Wealth Advisors LLC increased its position in shares of TG Therapeutics by 51.9% during the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company's stock worth $35,000 after purchasing an additional 365 shares in the last quarter. Hantz Financial Services Inc. increased its position in shares of TG Therapeutics by 82.7% during the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company's stock worth $37,000 after purchasing an additional 560 shares in the last quarter. Truvestments Capital LLC lifted its holdings in shares of TG Therapeutics by 172.4% in the 4th quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company's stock valued at $48,000 after purchasing an additional 1,026 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of TG Therapeutics in the 4th quarter valued at about $52,000. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics News Summary

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and lifted its price target on TG Therapeutics to $77, which is helping support the stock. TG Therapeutics (TGTX) Gets a Buy from H.C. Wainwright
• Positive Sentiment: Analysts also raised longer-term earnings forecasts for FY2028, FY2029, and FY2030, suggesting confidence in TG Therapeutics’ growth outlook.
• Neutral Sentiment: HC Wainwright lowered near-term estimates for Q2, Q3, Q4 2026 and FY2026, indicating some pressure on expected results in the next few quarters.
• Negative Sentiment: The cut to 2026 earnings expectations could limit enthusiasm if investors focus on short-term execution rather than the longer-term upside case.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company's research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.